Pfizer gets new rebuff from NICE for cancer drug

LONDON Thu Mar 28, 2013 12:02am GMT

A woman walks past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid

A woman walks past the Pfizer Inc. headquarters in New York, January 31, 2013.

Credit: Reuters/Brendan McDermid

Related Topics

Quotes

   

LONDON (Reuters) - Pfizer suffered a second rejection in two days from health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.

The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.

The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.

In both cases, the NICE recommendations are preliminary and subject to further consultation.

(Reporting by Ben Hirschler; Editing by Mark Potter)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.